JP2020510009A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020510009A5 JP2020510009A5 JP2019548368A JP2019548368A JP2020510009A5 JP 2020510009 A5 JP2020510009 A5 JP 2020510009A5 JP 2019548368 A JP2019548368 A JP 2019548368A JP 2019548368 A JP2019548368 A JP 2019548368A JP 2020510009 A5 JP2020510009 A5 JP 2020510009A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- compound
- hepatocellular carcinoma
- composition according
- fxr agonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 23
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 23
- 229940121360 farnesoid X receptor (fxr) agonists Drugs 0.000 claims description 22
- 229940125782 compound 2 Drugs 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 15
- 201000011510 cancer Diseases 0.000 claims description 14
- 229940125904 compound 1 Drugs 0.000 claims description 12
- 150000001413 amino acids Chemical class 0.000 claims description 10
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 5
- 206010004593 Bile duct cancer Diseases 0.000 claims description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 208000026900 bile duct neoplasm Diseases 0.000 claims description 4
- 201000010982 kidney cancer Diseases 0.000 claims description 4
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 claims description 4
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical group C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 claims description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical group NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 108010077895 Sarcosine Proteins 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims description 2
- 208000009956 adenocarcinoma Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000001394 metastastic effect Effects 0.000 claims description 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 2
- 230000000683 nonmetastatic effect Effects 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 229940043230 sarcosine Drugs 0.000 claims description 2
- 159000000000 sodium salts Chemical group 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 229960003080 taurine Drugs 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 14
- 238000000034 method Methods 0.000 description 15
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762468259P | 2017-03-07 | 2017-03-07 | |
| US62/468,259 | 2017-03-07 | ||
| PCT/US2017/052663 WO2018164715A1 (en) | 2017-03-07 | 2017-09-21 | Methods of treating cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020510009A JP2020510009A (ja) | 2020-04-02 |
| JP2020510009A5 true JP2020510009A5 (https=) | 2020-10-15 |
| JP7042836B2 JP7042836B2 (ja) | 2022-03-28 |
Family
ID=63447943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019548368A Active JP7042836B2 (ja) | 2017-03-07 | 2017-09-21 | 癌を処置する方法 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP3592357A4 (https=) |
| JP (1) | JP7042836B2 (https=) |
| KR (1) | KR20190122251A (https=) |
| CN (1) | CN110430882A (https=) |
| AU (1) | AU2017402623A1 (https=) |
| CA (1) | CA3055308A1 (https=) |
| IL (1) | IL269123A (https=) |
| TW (1) | TW201832768A (https=) |
| WO (1) | WO2018164715A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022011037A2 (en) * | 2020-07-07 | 2022-01-13 | The General Hospital Corporation | Interleukin 33 (il-33) inhibition for treatment of cancer, fibrosis and inflammation |
| WO2023043375A2 (en) * | 2021-09-16 | 2023-03-23 | Agency For Science, Technology And Research | Modulation of tjp1 expression to treat liver diseases |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050107475A1 (en) * | 2002-03-21 | 2005-05-19 | Jones Stacey A. | Methods of using farnesoid x receptor (frx) agonists |
| US7932244B2 (en) | 2006-06-27 | 2011-04-26 | Intercept Pharmaceuticals, Inc. | Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions |
| WO2013037482A1 (en) * | 2011-09-15 | 2013-03-21 | Phenex Pharmaceuticals Ag | Farnesoid x receptor agonists for cancer treatment and prevention |
| AU2013352288B2 (en) * | 2012-11-28 | 2017-11-23 | Intercept Pharmaceuticals, Inc. | Treatment of pulmonary disease |
| US10166246B2 (en) * | 2014-05-27 | 2019-01-01 | City Of Hope | TGR5 agonist complexes for treating diabetes and cancer |
| US11578097B2 (en) * | 2014-11-26 | 2023-02-14 | Enanta Pharmaceuticals, Inc. | Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof |
| PE20180690A1 (es) * | 2015-04-27 | 2018-04-23 | Intercept Pharmaceuticals Inc | Composiciones de acido obeticolico y metodos de uso |
| WO2017180577A1 (en) | 2016-04-13 | 2017-10-19 | Intercept Pharmaceuticals, Inc. | Methods of treating cancer |
-
2017
- 2017-08-11 TW TW106127326A patent/TW201832768A/zh unknown
- 2017-09-21 CA CA3055308A patent/CA3055308A1/en not_active Abandoned
- 2017-09-21 EP EP17899634.4A patent/EP3592357A4/en not_active Withdrawn
- 2017-09-21 JP JP2019548368A patent/JP7042836B2/ja active Active
- 2017-09-21 CN CN201780088500.7A patent/CN110430882A/zh active Pending
- 2017-09-21 WO PCT/US2017/052663 patent/WO2018164715A1/en not_active Ceased
- 2017-09-21 KR KR1020197029033A patent/KR20190122251A/ko not_active Withdrawn
- 2017-09-21 AU AU2017402623A patent/AU2017402623A1/en not_active Abandoned
-
2019
- 2019-09-04 IL IL26912319A patent/IL269123A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019511550A5 (https=) | ||
| JP2020514356A5 (https=) | ||
| EP3344253B1 (en) | Varlitinib for use in the treatment of resistant or refractory cancer | |
| Mody et al. | Clinical trials and progress in metastatic colon cancer | |
| JP7367910B2 (ja) | がんの処置 | |
| AU2015394135B2 (en) | Cancer treatments | |
| JP2017526662A5 (https=) | ||
| Mukkamalla et al. | Gastric cancer | |
| EA201290062A1 (ru) | Соединения, связывающие белки теплового шока, композиции и способы получения указанных соединений | |
| JP2021504399A5 (https=) | ||
| JP2015536964A5 (https=) | ||
| JP2017516775A5 (https=) | ||
| JP2020502271A5 (https=) | ||
| JP2016538344A5 (https=) | ||
| JP2011515397A5 (https=) | ||
| JP2008506681A5 (https=) | ||
| JP2016525097A5 (https=) | ||
| JP2017512791A5 (https=) | ||
| JP2019506392A5 (https=) | ||
| CA2922684A1 (en) | Combination of an alk inhibitor and a cdk inhibitor for the treatment of cell proliferative diseases | |
| JP2016519069A5 (https=) | ||
| JP2020510009A5 (https=) | ||
| JP2024088768A5 (https=) | ||
| JP2018514557A5 (https=) | ||
| JPWO2022270524A5 (https=) |